Safety, tolerability, and pharmacodynamic profile of DNL201 at dose levels demonstrating LRRK2 inhibition in Parkinson's Disease Patients with and without LRRK2 mutations

Authors
Category Primary study
ConferenceMovement Disorders
Year 2020
This article has no abstract
Epistemonikos ID: 57836aab10349e93ec9381f3d2722d6d8bd59282
First added on: Apr 30, 2026